Article Details
Retrieved on: 2024-07-29 20:05:24
Tags for this article:
Click the tags to see associated articles and topics
Summary
NurExone Biologic Inc. is engaging with Allele Capital Partners for capital market consultation, vital for advancing their ExoPTEN drug for CNS injuries, which aligns with drug discovery and development processes regulated by the FDA.
Article found on: www.globenewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here